(August 22, 2017) The Journal of Clinical Oncology recently published a study about the unmet need of genetic testing in women with breast and ovarian cancer. Women who fit eligibility criteria from the National Comprehensive Cancer Network (NCCN) took surveys focusing on discussions about genetic testing with a health professional, being advised to have genetic testing done, and actually having genetic testing done. 0.4% of the over 47,000 women surveyed had a history of ovarian cancer. In that subgroup, 15.1% had discussed it with a professional, 13.1% were advised to have genetic testing done, and 10.5% were actually tested. The study concluded that fewer than one in five women with a history of breast or ovarian cancer, included in the NCCN criteria, have had genetic testing. The study’s authors estimate that 1.2 to 1.3 million women do not receive genetic testing and advocate for a national action to fulfill this need.
Related Topics
Global Ovarian Cancer Research Consortium Awards Inaugural AI Accelerator Grant with Microsoft’s AI for Good Lab
$1 million global research award, plus an additional $1 million in compute support, advances AI-driven efforts to personalize ovarian cancer care The Global Ovarian Cancer Research Consortium today awarded its inaugural AI Accelerator Grant to an international team of researchers to examine whether artificial intelligence (AI) can improve how survival and treatment response are predicted … Continued
FDA Approves First Ovarian Cancer Immunotherapy for PD-L1–Positive Platinum-Resistant Disease
The U.S. Food and Drug Administration (FDA) has approved the first immunotherapy regimen shown to extend survival in a subset of ovarian cancer patients. The FDA authorized Keytruda (pembrolizumab), made by Merck, in combination with chemotherapy, for PD-L1–positive, platinum-resistant epithelial ovarian, fallopian tube, and primary peritoneal cancers. Keytruda plus weekly Taxol (paclitaxel), with or without … Continued
OCRA-Funded Study Provides Clear New Evidence That Opportunistic Salpingectomy Drastically Reduces Risk of Ovarian Cancer
A new study published February 2 in JAMA Network Open provides the clearest evidence to date that opportunistic salpingectomy—the removal of the fallopian tubes during another gynecologic surgery—can dramatically reduce the risk of ovarian cancer. Led by a B.C.-based international collaboration known as the Ovarian Cancer Observatory, the study found that people who underwent opportunistic … Continued